ABBOTT LABORATORIES (ABT:NYSE)
$112.47 0.88 (0.7886%)
Analysed ABBOTT LABORATORIES (ABT:NYSE) News Sources
Atrial Fibrillation Market Trends and Forecast 2026-2035 Featuring Profiles of Abbott, Boston Scientific, Medtronic, Johnson & Johnson, Novartis, and Sanofi
26-08-2026
yahoo.com
Pfizer vs. Abbott: Which Dividend Healthcare Stock Offers the Better Risk-Reward?
26-08-2026
yahoo.com
What Does Abbott Laboratories (ABT) FDA Clearance Mean For Its Diabetes Device Push?
27-08-2026
yahoo.com
Dexcom, Abbott await Medicare coverage expansion for CGMs
27-08-2026
medtechdive.com
Abbott's next-generation Amulet 360™ device receives CE Mark to treat people with atrial fibrillation at risk of stroke
27-08-2026
yahoo.com
The FDA Just Gave Abbott a Diabetes First. Is Its Beaten-Down Stock Ready to Wake Up?
27-08-2026
247wallst.com
Abbott (ABT) Stock Sinks As Market Gains: Here's Why
27-08-2026
yahoo.com
FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking
28-08-2026
yahoo.com
Abbott wins CE mark for new LAA closure device
28-08-2026
medtechdive.com
Avricore Grants Options
28-08-2026
yahoo.com
What is the current price of ABBOTT LABORATORIES (ABT:NYSE)?
The current price of ABBOTT LABORATORIES (ABT:NYSE) is $112.47.
ABBOTT LABORATORIES (ABT:NYSE) absolute price change since previous trading day?
The absolute price change of ABBOTT LABORATORIES (ABT:NYSE) since the previous trading day is $0.88.
ABBOTT LABORATORIES (ABT:NYSE) percentage price change since previous trading day?
The percentage price change of ABBOTT LABORATORIES (ABT:NYSE) since the previous trading day is 0.7886%.
What is the most recent average sentiment score for ABBOTT LABORATORIES (ABT:NYSE)?
The most recent average sentiment score for ABBOTT LABORATORIES (ABT:NYSE) is 70 out of 100.
What is the most recent average sentiment for ABBOTT LABORATORIES (ABT:NYSE)?
The most recent sentiment for ABBOTT LABORATORIES (ABT:NYSE) is .
SEC-8K** Filing Available For ABBOTT LABORATORIES (ABT:NYSE)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.